Report Overview

The Indian Hepatitis Therapeutics Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period (2019-2028).

Hepatitis is an inflammation, or swelling, of the liver. The average estimated carrier rate of hepatitis B virus (HBV) in India is 4%, with a total pool of approximately 36 million carriers. Wide variations in social, economic, and health factors in different regions may explain variations in carrier rates from one part of the country to another.In India, HBV is reported to be responsible for 70% of cases of chronic hepatitis and 80% of cases of cirrhosis of the liver. About 60% of patients with hepatocellular carcinoma are HBV marker positive. The frequency of hepatitis C has been reported to be 1-2 per cent among voluntary blood donors^. About 15-30 per cent cases of acute hepatitis in India is due to HBV.Rise in the consumption of alcohol, infections from contaminated blood sources, and increase in the number of autoimmune diseases are leading to a rise in the cases of inflammation of the liver. Viral hepatitis is an important source of morbidity and mortality in India. Growing occurrence of hepatitis and higher death rate are major factors driving the need for specialized treatments and medicines, so propelling the growth of the hepatitis therapeutics market during the forecast period.

 

Market Drivers

An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the Indian hepatitis therapeutics market. Growing healthcare costs coupled with the decline in R&D activities and Medicare budgets are some of the key factors affecting the profitability of players and impact the market dynamics to a great extent. Other factors are growing awareness pertaining to the availability of generic drugs is also expected to increase the treatment rate and improve overall healthcare outcomes. Increase in the usage of unsterilized equipment and infected syringes, medication errors, and transfusion of infectious blood are leading to an increase in the incidence of viral diseases such as Hepatitis C.